number. This view is supported by the results from hierarchical cluster analyses including different numbers of genes with heterogenous expression, which were selected according to defined criteria ( Figure 1) . We found several genes that were heterogenously expressed in our samples indicating that a heterogenous alteration of gene expression by imatinib could be possible. However, we could not identify groups that were associated with imatinib treatment supporting the results from the SAM algorithm that there were no uniform imatinib-induced changes in gene expression.
In conclusion, after reaching major molecular remission during first-line treatment with 400 mg imatinib per day, no uniform influence of the tyrosine kinase inhibitor on gene expression patterns in Ph-negative CD34 þ stem and progenitor cells was observed in vivo. Therefore, based on our gene expression data we found no evidence for a major functional disturbance of Ph-negative hematopoiesis using imatinib as firstline therapy in CML.
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This work was supported by the Leukämie Liga e.V., Dü sseldorf. Between January 1997 and January 2004, we performed cytogenetics and fluorescence in situ hybridization (FISH) analyses in 985 patients with CML. A total of 628 patients were treated with imatinib and 357 patients with interferon alpha (IFN). A minority of cases were treated in addition to IFN with hydroxyurea (HU), busulfan or thioguanin. All cases were diagnosed and treated at our own institution or samples were sent for diagnosis and follow-up studies to our reference laboratory. In all, 128/985 patients were included in another report on clonal evolution during imatinib treatment. 2 All 985 cases underwent routine cytogenetic analysis, interphase FISH and real-time PCR for BCR-ABL according to standard protocols at diagnosis of CML. 3 Complete cytogenetic remission was defined as 0% Philadelphia-positive (Ph þ ) metaphases; major cytogenetic response: 1-34% Ph þ metaphases; minor cytogenetic response: 35-95% Ph þ metaphases; no response: 96-100% Ph þ metaphases.
Philadelphia independent clonal evolution was found in 2.4% of all patients receiving imatinib (15/628) and in 0.2% of all patients receiving IFN (1/357 patients). The incidence of Philadelphia independent clonal evolution during imatinib was in the range of the literature (2-17%). 1, 4, 5 The lower incidence of Philadelphia independent clonal evolution in patients with interferon corresponds to the small number of anecdotal reports in the literature. 1, 6 Imatinib was started in 14/15 patients in chronic phase of CML. Accelerated phase was found in one case at the start of imatinib treatment. One patient demonstrated Ph À BCR-ABLpositive CML (patient #10). Only one patient with new independent markers received IFN as first-line therapy, which had been started in chronic phase. Patients' characteristics are demonstrated in Table 1 .
Imatinib was first-line therapy in 40% (6/15). In total, 60% of all imatinib patients (8/14) had received pretreatment with IFN, hydroxyurea, busulfan, cytarabin or anagrelide prior to imatinib therapy. In previous studies, the proportion of patients who had received pretreatment was higher. 1, 4 The median interval from the start of therapy with imatinib or IFN to the first observation of the Ph independent clonal aberrations was 7.5 months (range 3-15 months). This corresponds to the literature, reporting median intervals from 5 to 24 months. 1, 7, 8 From diagnosis of CML to the first occurrence of the Ph independent clonal changes, the median Interval from diagnosis of CML to the first occurrence of the Ph independent clonal changes.
b
Interval from start of imatinib/IFN therapy to the first occurrence of the Ph independent clonal changes. Patient #3 was treated with imatinib as first-line therapy for CML in chronic phase with 100% Ph þ metaphases. Trisomy 8 in Ph independent cells was detected 8 months after the start of imatinib therapy in 8% of all metaphases. The proportion of Ph þ metaphases had decreased to 76%. At 19 months after the start of imatinib therapy, the patient had reached complete hematologic remission and major cytogenetic response with a reduction of the Ph þ metaphases to 10%. The proportion of Ph independent metaphases with trisomy 8 showed an increase to 90%. At 31 months after the start of imatinib therapy, the cytogenetic response to imatinib deteriorated with an increase of the Ph þ metaphases from 10 to 36%. The Ph À metaphases with trisomy 8 decreased from 90 to 36%.
SPOTLIGHT
Spotlight Correspondence interval was 17.5 months (range 6-69 months). After the detection of the Philadelphia independent clone, we performed cytogenetic follow-up in our patients with a range of 0-27 months.
In the 15 cases receiving imatinib, the most frequent chromosomal change in Ph À cells was trisomy 8 (67%; 10/15 cases). Monosomy 7 was found in three cases (20%). One patient demonstrated del(7)(q11q22). A reciprocal translocation t(8;11)(q22;q23) was found in another case.
However, Philadelphia independent clonal changes demonstrate a heterogenous spectrum. Trisomy 8 and monosomy 7 were found as the most frequent abnormalities. 1, 7 Reciprocal translocations were described in Philadelphia independent clonal evolution in the literature. 1, 4, 8 Reciprocal translocations involving 8q have not been reported so far in Philadelphia independent clonal evolution.
The patient with IFN treatment demonstrated trisomy 8 in Ph À cells. Trisomy 8 in Ph independent cells in association to IFN in CML was described before as the most frequent aberration. 6 At the onset of the Ph independent clonal changes during treatment with imatinib or interferon, complete cytogenetic remission was found in another 25% (4/16 patients) and major cytogenetic response in 25% (4/16). Minor cytogenetic remission was observed in 50% (8/16). Our findings were in contrast to the literature reporting that most patients with evidence of Ph independent clonal evolution were at complete cytogenetic remission or showed major cytogenetic response. [6] [7] [8] In all, 38% (6/16) of all patients demonstrated also clonal evolution with the Philadelphia translocation. A temporal coincidence of Ph þ and Ph independent clonal evolution at the onset of the chromosomal changes in Ph À cells was found in 31% (5/16). months from start of imatinib % of metaphases Ph+ metaphases metaphases with double Ph chromosome Ph-+8 metaphases normal metaphases Figure 3 Patient #9 was treated with IFN for CML in chronic phase. At 8 months after IFN had been started, major cytogenetic response was documented with a decrease of Ph þ metaphases from 96 to 12%. At this time point, clonal evolution in the Ph þ cells was detected with a doubling of the Ph chromosome. At 28 months after start of interferon, treatment was changed to imatinib because of relapse to chronic phase and development of refractoriness to interferon. At 8 months after change to imatinib, major cytogenetic response with a reduction of the Ph þ metaphases from 100 to 12% was documented. Cytomorphological examination demonstrated complete hematologic remission. At this time point, Ph independent cells with trisomy 8 were detected in 53% of all metaphases. Normal metaphases accounted for 35%. The follow-ups 12 and 16 months after the start of imatinib therapy showed a decrease of the Ph À þ 8 clone from 53 to 16% and an increase of the normal metaphases from 35 to 72%. CML showed major cytogenetic response (with 12% Ph þ metaphases) and hematologic complete remission.
SPOTLIGHT Spotlight Correspondence
At the onset of the Philadelphia independent clonal changes, 10/12 cases (83%) demonstrated complete hematologic remission of CML at cytomorphologic examination of bone marrow smears. Treatment-associated myelodysplastic syndrome (MDS) was observed in 2/16 patients (13%), both with evidence of Ph independent monosomy 7 during imatinib. One patient demonstrated MDS with the subtype refractory anemia with ringsideroblasts (MDS/RARS) 3 months after the start of imatinib therapy in association to the primary detection of Ph independent monosomy 7 (#14). At this time point, the patient had achieved major cytogenetic response of CML. This patient had a history of intensive pretreatment with IFN, busulfan, hydroxyurea, and anagrelide over 13 months.
In another patient (#13), we diagnosed MDS of the subtype refractory anemia with an excess of blasts (MDS/RAEB-2) with 15% bone marrow blasts and trilineage dysplasia 6 months after the occurrence of the Ph independent monosomy 7. At this time, CML was in complete cytogenetic remission. The patient was treated with imatinib for 11 months, following pretreatment with hydroxyurea, IFN, and cytarabin for another 64 months before.
The pathogenesis of Ph independent evolution is still under discussion. Genomic instability in patients with CML was suggested. 7 Further, a multistep model of the development of CML was discussed. This implicates that the Ph translocation induces CML with the contribution of other clonal changes. Imatinib could select these pre-existing chromosomal changes. 5 This hypothesis is underlined by the retrospective FISH analyses performed by Terre et al 1 who were able to detect the respective Ph independent clonal aberration in 4/15 cases in samples that had been archived before the start of imatinib therapy. It is also possible that imatinib may induce cytogenetic abnormalities. It was suggested that Ph independent clonal evolution could be induced by pretreatment or selected by imatinib. 4 The permanent inhibition of the ABL gene with its association to proteins involved in DNA repair could lead to an accumulation of genetic damage. 4 This pathogenesis can be discussed in some patients, but is not sufficient for explanation in all cases. 8 It has to be discussed further if Ph independent clonal changed cells have a proliferation advantage in all cases. Bumm et al 4 observed in all patients an increase of the proportion of Ph independent cells with clonal changes during continuation of imatinib.
We performed close cytogenetic follow-up in three cases after Ph independent clonal aberration had been detected. These three patients were treated with imatinib and all demonstrated trisomy 8. In contrast to this observation, Ph independent clonal changed metaphases, normal metaphases, and Ph þ metaphases did not follow a recurrent pattern in three of our patients with trisomy 8 (see Figures 1-3) .
None of the 11 patients with trisomy 8 during imatinib or interferon treatment showed cytomorphological features of MDS or AML. In contrast, we observed treatment-associated MDS in two of four cases showing Ph independent monosomy 7 or deletion of 7q during imatinib treatment.
Some more cases of MDS and of transformation to AML were reported in association to monosomy 7 during imatinib treatment of CML. 4 Monosomy 7 is associated with an inferior prognosis in MDS and AML. However, the limited follow-up and the limited samples do not allow definite conclusions with respect to the prognostic role of these specific abnormalities in Ph independent clonal evolution.
Preliminary data suggest that Ph independent clonal evolution is associated with a higher risk of secondary MDS or AML. Thus, it is essential to identify cases with this specific risk profile in a clinical setting. This is only possible by continuation of cytogenetic follow-up even after complete or major cytogenetic response to imatinib to identify all cases of Ph independent cytogenetic aberrations and to achieve more understanding for the necessary therapeutical strategies in cases demonstrating this phenomenon. It is unclear whether patients showing Ph independent clonal changes should be taken off the study or offered an allogeneic stem cell transplantation. Grosshadern, Ludwig-Maximilians-University, Munich, Germany; and
